Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Human CD229/LY9 Antibody (SAA1619)

Catalog #:   RHJ59601 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: ELISA
Accession: Q9HBG7
Overview

Catalog No.

RHJ59601

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

SLAM family member 3, Lymphocyte antigen 9, Cell surface molecule Ly-9, T-lymphocyte surface antigen Ly-9, Signaling lymphocytic activation molecule 3, CD229, LY9, SLAMF3

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9HBG7

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA1619

Data Image
References

Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab-Treated Patients With Multiple Myeloma., PMID:39267340

SLAMF3 promotes Th17 differentiation and is reversed by iguratimod through JAK1/STAT3 pathway in primary Sjögren's syndrome., PMID:38061117

Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma-An evidence-based approach., PMID:36403963

Immunophenotypic Characterization and Ploidy Analysis of Neoplastic Plasma Cells by Multiparametric Flow Cytometry., PMID:35747566

CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma., PMID:35565280

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion., PMID:35490197

Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity., PMID:35078657

CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab., PMID:33017079

Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study., PMID:32781097

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide., PMID:32034142

Upregulation of SLAMF3 on human T cells is induced by palmitic acid through the STAT5-PI3K/Akt pathway and features the chronic inflammatory profiles of type 2 diabetes., PMID:31332162

Ly9 (CD229) Antibody Targeting Depletes Marginal Zone and Germinal Center B Cells in Lymphoid Tissues and Reduces Salivary Gland Inflammation in a Mouse Model of Sjögren's Syndrome., PMID:30519241

The role of surface molecule CD229 in Multiple Myeloma., PMID:30326256

Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies., PMID:29316178

Cell surface markers for the identification and study of human naive pluripotent stem cells., PMID:29227830

Ly9 (SLAMF3) receptor differentially regulates iNKT cell development and activation in mice., PMID:28980301

Novel anti-myeloma immunotherapies targeting the SLAM family of receptors., PMID:28638731

Targeting of Ly9 (CD229) Disrupts Marginal Zone and B1 B Cell Homeostasis and Antibody Responses., PMID:26667173

Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents., PMID:26287276

Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases., PMID:26130131

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma., PMID:26001047

The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection., PMID:24927415

Systemic lupus erythematosus immune complexes increase the expression of SLAM family members CD319 (CRACC) and CD229 (LY-9) on plasmacytoid dendritic cells and CD319 on CD56(dim) NK cells., PMID:23956418

Ly9 (CD229) Cell-Surface Receptor is Crucial for the Development of Spontaneous Autoantibody Production to Nuclear Antigens., PMID:23914190

CD3-T cell receptor co-stimulation through SLAMF3 and SLAMF6 receptors enhances RORγt recruitment to the IL17A promoter in human T lymphocytes., PMID:22989874

Human cytomegalovirus UL7, a homologue of the SLAM-family receptor CD229, impairs cytokine production., PMID:21670740

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma., PMID:21606160

Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010., PMID:20951742

Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells., PMID:20933013

Analysis of HLDA9 mAbs on plasmacytoid dendritic cells., PMID:20933012

Differential expression of SLAMS and other modulatory molecules by human plasma cells during normal maturation., PMID:20923684

Characterization of mouse CD229 (Ly9), a leukocyte cell surface molecule of the CD150 (SLAM) family., PMID:17919264

Ly9 (CD229)-deficient mice exhibit T cell defects yet do not share several phenotypic characteristics associated with SLAM- and SAP-deficient mice., PMID:16365421

Fine-tuning of immune responses by SLAM-related receptors., PMID:16365151

CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically through its N-terminal domain and relocalizes to the immunological synapse., PMID:15905546

Identification of Grb2 as a novel binding partner of the signaling lymphocytic activation molecule-associated protein binding receptor CD229., PMID:15879090

Molecular and cellular pathogenesis of X-linked lymphoproliferative disease., PMID:15661030

Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4)., PMID:15245368

Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells., PMID:15162436

Functional requirements for interactions between CD84 and Src homology 2 domain-containing proteins and their contribution to human T cell activation., PMID:12928397

The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2)., PMID:12621057

Mouse novel Ly9: a new member of the expanding CD150 (SLAM) family of leukocyte cell-surface receptors., PMID:12242590

Identification and characterization of SF2000 and SF2001, two new members of the immune receptor SLAM/CD2 family., PMID:11862385

Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells., PMID:11689425

CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: adhesion is mediated by Ig-like domain 1., PMID:11564780

Activation of lymphocytes inhibits human monocyte to macrophage differentiation., PMID:11563672

CD150 is a member of a family of genes that encode glycoproteins on the surface of hematopoietic cells., PMID:11486275

XLP: one gene, many players., PMID:11414739

Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9., PMID:11369645

Genetic approach to insight into the immunobiology of human dendritic cells and identification of CD84-H1, a novel CD84 homologue., PMID:11300479

Datasheet
$ 328
Product specifications
100 μg 328 1 mg 1640

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human CD229/LY9 Antibody (SAA1619) [RHJ59601]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only